significant tumor regressions in mice with established carcinomas , sarcomas , and melanomas and in humans with advanced cancers have been observed following immunotherapy with lymphokine-activated killer ( lak ) cells and recombinant interleukin-2 ( il-2 ) .
C0086418
humans
C0021756
recombinant